Bosutinib R&D and manufacturer

Bosutinib (Bosutinib) is developed and manufactured by Pfizer Pharmaceuticals (Pfizer Inc.). Pfizer is a world-renowned biopharmaceutical company headquartered in the United States and founded in 1849. The company develops and manufactures a broad range of pharmaceutical products across multiple therapeutic areas, including cardiovascular, immunology, neurology, oncology and more.

Bosutinib is a tyrosine kinase inhibitor mainly used to treat chronic myelogenous leukemia (CML). The pharmaceutical company Pfizer has invested significant resources in its research and development to bring this medicine to market and provide new treatment options for patients. The drug's development process went through multiple stages, including clinical trials and regulatory approval, and was finally approved for clinical treatment in certain cases.

As one of the world's leading pharmaceutical companies, Pfizer has strong R&D capabilities and a global production network. Through continuous innovation, the company promotes scientific research and strives to develop innovative drugs to meet the medical needs of different patient groups.

Bosutinib is not yet available in China, so patients cannot purchase it domestically and need to purchase it through overseas channels. There are original drugs and generic drugs of bosutinib abroad. The original drugs include the Turkish original drug and the European version of the original drug. The Turkish version of the original drug costs about 2,000 to 3,000 yuan, and the European version of the original drug costs about 30,000 yuan. In addition, there are cheaper generic drugs, which cost more than one thousand yuan, and the ingredients of the original drugs and generic drugs are basically the same.